ANKRD20A1

Across TCGA pan-cancer cohorts, ANKRD20A1 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ANKRD20A1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ANKRD20A1 RNA is repressed in tumor relative to normal tissue. In most cancer types ANKRD20A1 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

THCA, BRCA, and COAD are the cancer types where ANKRD20A1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKRD20A1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	All	−0.080	<.001	9	view →
BRCA	Female	All	−0.036	.001	8	view →
COAD	All	All	−0.030	.003	6	view →
HNSC	All	All	−0.029	.032	3	view →
LUAD	Female	II,III,IV	−0.043	.007	2	view →
KIRC	Female	All	+0.032	.020	2	view →
STAD	All	IV	+0.063	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ANKRD20A1–THCA

Open the THCA breakdown →